Xbrane Biopharma AB (publ) ("Xbrane" or "the Company”) represented by Martin Åmark, CEO, presents at the Småbolagsdagen February 24, 2021. Follow the presentation of Xbrane’s development focusing on the up-coming draft read-out from the phase III data for the biosimilarcandidate Xlucane and the planned application for market authorization.
Time: February 24, kl. 08.00 – 13.10
Time and weblink to Xbrane´s presentation: kl 10.40, https://tv.streamfabriken.com/2021-02-24-xbrane-biopharma
The Småbolagsdagen is a collaboration between Financial Hearings and Börsveckan. The companies present their operations and afterwards follows a question-and-answer session led by Lars Frick, an analyst at Börsveckan.
Martin Åmark, CEO
M: +46 (0) 763-093 777
Anette Lindqvist, CFO / IR
M: +46 (0) 763 256 090
Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the SEK 106 billions ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally three biosimilars in its pipeline targeting SEK 100 billions in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.